ATE252386T1 - Galantamin-zusammensetzung mit gesteuerter freisetzung - Google Patents

Galantamin-zusammensetzung mit gesteuerter freisetzung

Info

Publication number
ATE252386T1
ATE252386T1 AT99965527T AT99965527T ATE252386T1 AT E252386 T1 ATE252386 T1 AT E252386T1 AT 99965527 T AT99965527 T AT 99965527T AT 99965527 T AT99965527 T AT 99965527T AT E252386 T1 ATE252386 T1 AT E252386T1
Authority
AT
Austria
Prior art keywords
galantamin
composition
controlled release
release
controlled
Prior art date
Application number
AT99965527T
Other languages
English (en)
Inventor
John Paul Mcgee
Paul Marie V Gilis
Weer Marc M G De
Conde Valentin F De
Bruijn Herman J De
Dycke Frederic A Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE252386(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE252386T1 publication Critical patent/ATE252386T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT99965527T 1998-12-24 1999-12-20 Galantamin-zusammensetzung mit gesteuerter freisetzung ATE252386T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98204447 1998-12-24
PCT/EP1999/010257 WO2000038686A1 (en) 1998-12-24 1999-12-20 Controlled release galantamine composition

Publications (1)

Publication Number Publication Date
ATE252386T1 true ATE252386T1 (de) 2003-11-15

Family

ID=8234559

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99965527T ATE252386T1 (de) 1998-12-24 1999-12-20 Galantamin-zusammensetzung mit gesteuerter freisetzung

Country Status (35)

Country Link
US (3) US7160559B1 (de)
EP (1) EP1140105B1 (de)
JP (1) JP2002533396A (de)
KR (1) KR100437105B1 (de)
CN (1) CN100370990C (de)
AP (1) AP1414A (de)
AR (2) AR022008A1 (de)
AT (1) ATE252386T1 (de)
AU (1) AU775914B2 (de)
BG (1) BG65306B1 (de)
BR (1) BR9916835A (de)
CA (1) CA2358062C (de)
CZ (1) CZ301658B6 (de)
DE (1) DE69912311T2 (de)
DK (1) DK1140105T3 (de)
EA (1) EA004936B1 (de)
EE (1) EE04996B1 (de)
ES (1) ES2211215T3 (de)
HR (1) HRP20010463B1 (de)
HU (1) HUP0104778A3 (de)
ID (1) ID29021A (de)
IL (2) IL143899A0 (de)
MY (1) MY122411A (de)
NO (1) NO327988B1 (de)
NZ (1) NZ511643A (de)
OA (1) OA11740A (de)
PL (1) PL349501A1 (de)
PT (1) PT1140105E (de)
SI (1) SI1140105T1 (de)
SK (1) SK287676B6 (de)
TR (1) TR200101822T2 (de)
TW (1) TWI262079B (de)
UA (1) UA79578C2 (de)
WO (1) WO2000038686A1 (de)
ZA (1) ZA200105132B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
AU775914B2 (en) 1998-12-24 2004-08-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
WO2003032914A2 (en) * 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
PT1578422E (pt) 2002-12-20 2007-06-14 Niconovum Ab Material particulado contendo nicotina fisicamente e quimicamente estável
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
US7250258B2 (en) 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
EP2340813A1 (de) * 2003-12-31 2011-07-06 Actavis Group PTC ehf. Feste Darreichungsformen von Galantamin
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US20050142193A1 (en) * 2003-12-31 2005-06-30 Lijuan Tang Galantamine formulations
GB0408308D0 (en) * 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
MX2007007836A (es) * 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
CN101166543B (zh) * 2005-04-28 2014-07-16 卫材R&D管理有限公司 含抗痴呆药物的组合物
WO2007029081A1 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Galantamine-containing controlled release oral dosage forms, processes for the preparation thereof and use for the manufacture of a medicament
US20070092568A1 (en) * 2005-10-10 2007-04-26 Gore Subhash P Galantamine compositions
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
HUE029173T2 (hu) * 2006-04-26 2017-02-28 Alphapharm Pty Ltd Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot
WO2008062426A2 (en) * 2006-08-02 2008-05-29 Emcure Pharmaceuticals Limited Formulation of benzazepine derivatives
US7955622B2 (en) 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
DE102006056697A1 (de) * 2006-11-30 2008-06-05 Ratiopharm Gmbh Galanthamin-haltiges Arzneimittel mit kontrollierter Freisetzung
PL2120878T3 (pl) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
KR100782310B1 (ko) 2007-03-22 2007-12-06 현대약품 주식회사 갈란타민 또는 이의 약학적으로 허용 가능한 염을 포함하는약학 조성물
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
WO2009024858A1 (en) * 2007-08-22 2009-02-26 Aurobindo Pharma Limited Controlled release dosage form of galantamine
WO2009043914A1 (en) * 2007-10-05 2009-04-09 Krka, D.D., Novo Mesto Multi particulate matrix system containing galantamine
EP2044933A1 (de) * 2007-10-05 2009-04-08 KRKA, D.D., Novo Mesto Mehrteilchen-Matrixsystem mit Galantamin
CA2615137A1 (en) * 2007-12-17 2009-06-17 Pharmascience Inc. Single layered controlled release therapeutic system
EP2116232B1 (de) 2008-05-09 2012-02-15 Ratiopharm GmbH Galanthaminhaltiges Arzneimittel mit kontrollierter Freisetzung
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA2781826A1 (en) 2009-11-26 2011-06-03 Usv Limited Controlled release pharmaceutical compositions of galantamine
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
GR1007767B (el) 2011-07-26 2012-11-19 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα παρατεταμενης αποδεσμευσης περιεχον γκαλανταμινη και μεθοδος για την παρασκευη αυτου
EP3563849A3 (de) * 2012-10-25 2020-02-12 The General Hospital Corporation Kombinationstherapien zur behandlung von morbus alzheimer und verwandten erkrankungen
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
GB201620095D0 (en) * 2016-11-28 2017-01-11 Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And Novel use
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
WO2018213838A1 (en) * 2017-05-19 2018-11-22 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
MX2021004586A (es) 2018-11-19 2021-06-15 Supernus Pharmaceuticals Inc Uso de dosis mas altas de formulaciones de huperzina de liberacion modificada.
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
BG67408B1 (bg) 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
WO2022146914A1 (en) 2020-12-28 2022-07-07 The General Hospital Corporation Cromolyn derivatives and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
EP0363415B1 (de) 1987-05-04 2008-10-15 Davis, Bonnie Mittel zur behandlung der alzheimer-krankheit
CA1326632C (en) 1988-10-26 1994-02-01 Bonnie Davis Long-active drug formulations comprising galanthamine for treatment of alzheimer's disease
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
AT397345B (de) 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
WO1992020327A1 (en) * 1991-05-14 1992-11-26 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
DE4301782C1 (de) 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
ES2107235T3 (es) * 1993-06-14 1997-11-16 Janssen Pharmaceutica Nv Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina.
DE4319760A1 (de) * 1993-06-15 1994-12-22 Bayer Ag Ipsapiron Arzneimittelzubereitung
JPH09500645A (ja) * 1993-07-22 1997-01-21 ワーナー−ランバート・コンパニー 制御放出タクリン薬物送達システムおよびその製造方法
EP1442745A1 (de) * 1993-10-07 2004-08-04 Euro-Celtique Oral anzuwendende opioidhaltige Zusammensetzungen mit verlängerter Wirkung
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
DE4342174C1 (de) * 1993-12-10 1995-05-11 Lohmann Therapie Syst Lts Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
GB9514821D0 (en) 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
JP3833314B2 (ja) * 1995-09-08 2006-10-11 武田薬品工業株式会社 発泡性組成物およびその製造方法
JP3693270B2 (ja) 1995-10-12 2005-09-07 旭化成ケミカルズ株式会社 フィルムコーティング顆粒およびその製造方法
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
JP3134187B2 (ja) 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
WO1998022072A1 (en) * 1996-11-19 1998-05-28 The Procter & Gamble Company Compliance package and method of improving or aiding patient compliance for complex drug regimens
JPH10231242A (ja) * 1997-02-20 1998-09-02 Taiyo Yakuhin Kogyo Kk 持続性ジクロフェナクナトリウム組成物
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TW477702B (en) * 1997-10-23 2002-03-01 Dev Center Biotechnology Controlled release tacrine dosage form
AU1282099A (en) 1997-10-29 1999-05-17 Bonnie M. Davis Method for treatment of disorders of attention
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
AU775914B2 (en) * 1998-12-24 2004-08-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
AUPP891299A0 (en) 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
US6273260B1 (en) * 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system

Also Published As

Publication number Publication date
CN1331596A (zh) 2002-01-16
US7160559B1 (en) 2007-01-09
US20060062856A1 (en) 2006-03-23
DK1140105T3 (da) 2004-02-23
EE200100319A (et) 2002-10-15
MY122411A (en) 2006-04-29
CZ301658B6 (cs) 2010-05-19
WO2000038686A1 (en) 2000-07-06
BG65306B1 (bg) 2008-01-31
HRP20010463A2 (en) 2002-08-31
NZ511643A (en) 2003-07-25
HUP0104778A2 (hu) 2002-04-29
HRP20010463B1 (hr) 2011-02-28
AU2100600A (en) 2000-07-31
CA2358062C (en) 2006-12-19
EP1140105A1 (de) 2001-10-10
JP2002533396A (ja) 2002-10-08
CZ20012182A3 (cs) 2002-01-16
CA2358062A1 (en) 2000-07-06
EP1140105B1 (de) 2003-10-22
PL349501A1 (en) 2002-07-29
HK1043062A1 (zh) 2002-09-06
KR100437105B1 (ko) 2004-06-23
EE04996B1 (et) 2008-04-15
ES2211215T3 (es) 2004-07-01
AR022008A1 (es) 2002-09-04
EA004936B1 (ru) 2004-10-28
PT1140105E (pt) 2004-03-31
UA79578C2 (en) 2007-07-10
HUP0104778A3 (en) 2004-05-28
ID29021A (id) 2001-07-26
AU775914B2 (en) 2004-08-19
IL143899A (en) 2006-04-10
NO20012857D0 (no) 2001-06-08
OA11740A (en) 2005-05-13
KR20010075715A (ko) 2001-08-09
BR9916835A (pt) 2001-09-25
ZA200105132B (en) 2002-06-21
CN100370990C (zh) 2008-02-27
DE69912311D1 (de) 2003-11-27
TWI262079B (en) 2006-09-21
US20060093671A1 (en) 2006-05-04
IL143899A0 (en) 2002-04-21
BG105564A (en) 2002-01-31
TR200101822T2 (tr) 2001-11-21
AP2001002219A0 (en) 2001-09-30
SI1140105T1 (en) 2004-04-30
SK287676B6 (sk) 2011-05-06
SK8862001A3 (en) 2002-02-05
NO20012857L (no) 2001-06-08
DE69912311T2 (de) 2004-07-29
AR066313A2 (es) 2009-08-12
NO327988B1 (no) 2009-11-02
AP1414A (en) 2005-06-13
EA200100713A1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
ATE252386T1 (de) Galantamin-zusammensetzung mit gesteuerter freisetzung
DK0922386T3 (da) Sammensætninger med reguleret frigivelse
DE60043447D1 (de) Zusammensetzungen mit kontrollierter freigabe enthaltend nimesulid
ID26186A (id) Komposisi sampo
ID28694A (id) Komposisi sampo
ID29430A (id) Komposisi herbisida
DE69506086D1 (de) Zusammensetzung mit gesteuerter freisetzung
ID26926A (id) Komposisi shampo pembentuk mode
DK0945132T3 (da) Ibuprofen-præparat
DE69826289D1 (de) Mikroverkapselte ngf zusammensetzungen mit geregelter freigabe
DE69905371D1 (de) Härtbare zusammensetzung
DE69925322D1 (de) Polymerisierbare Zusammensetzung
ATE269075T1 (de) Makrolid-formulierung mit verzögerter wirkstoffabgabe
NO20004758L (no) Vaksinesammensetning
DK0954966T3 (da) Polymere sammensætninger med reguleret frigivelse
ID25508A (id) Komposisi dematologis
DK0880892T5 (da) Midler med reguleret frigivelse
ATE254907T1 (de) Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe
ATE241597T1 (de) Geruchsmaskierte dimethylsulfid-zusammensetzung
ID23458A (id) Bentuk sediaan nefazodon
DE69928862D1 (de) Zusammensetzung
DE69942892D1 (de) Gaserzeugende zusammensetzung
DE60103582D1 (de) Zusammensetzungen mit kontrollierter Freisetzung
DE69942571D1 (de) Lagerungsbeständige polymerisierbare Zusammensetzung
ID21009A (id) Komposisi untuk supositori

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140105

Country of ref document: EP